<sup>90</sup>Y Radioembolization versus Drug-eluting Bead Chemoembolization for Unresectable Hepatocellular Carcinoma: Results from the TRACE Phase II Randomized Controlled Trial
Elisabeth Dhondt, Bieke Lambert, Laurens Hermie, Lynn Huyck, Peter Vanlangenhove, Anja Geerts, Xavier Verhelst, Maridi Aerts, Aude Vanlander, Frederik Berrevoet, Roberto Troisi, Hans Van Vlierberghe, Luc Defreyne
Abstract
= .24) were similar in the safety groups. At the interim, the HR for the primary end point, TTP, was less than 0.39, meeting the criteria to halt the study. Conclusion With similar safety profile, yttrium 90 radioembolization conferred superior tumor control and survival compared with chemoembolization using drug-eluting beads in selected participants with early or intermediate hepatocellular carcinoma. Clinical trial registration no. NCT01381211 © RSNA, 2022
Topics & Concepts
MedicineHepatocellular carcinomaHazard ratioClinical endpointInterim analysisRandomized controlled trialProspective cohort studyInternal medicineSingle CenterSurgeryIntention-to-treat analysisConfidence intervalGastroenterologyHepatocellular Carcinoma Treatment and PrognosisRenal cell carcinoma treatmentLiver Disease and Transplantation